QSAR DAN MOLECULAR DOCKING SENYAWA DERIVAT LUMIRACOXIB, INHIBITOR OKSIGENASI 2-AG PADA TERAPI INFLAMASI

  • Nursalam Hamzah Jurusan Farmasi, Fakultas Ilmu Kesehatan, Universitas Islam Negeri Alauddin Makassar
  • Haeria Haeria
  • Nurul Muhlisa Mus

Abstract

Cyclooxygenase-2 (COX-2) is a molecular target that is widely studied and has a crucial role in the last decade. The high contribution of COX-2 in inflammation and inhibiting function of 2-AG oxygenation by COX-2 inhibitors in inflammatory, open a new chapter dealing with the research on inhibition of COX-2. The purpose of this study is to determine the physical-chemical properties that play an important role in the activity of lumiracoxib derivates based QSAR equation and look from the interaction of ligand-receptor through docking simulations. Statistical analysis was calculated by multilinear regression analysis using SPSS Statistics 17.0. Leave One Out cross validation, Pearson correlation, and the relationship of IC50 experiments and IC50 predictions curve are used to obtain QSAR equation with significantly statistic criteria. Molecular docking to study ligand-receptor interactions, performed using MOE 2009.10. Hydrogen bonds with amino acid residues on the receptor 4OTY include Ser A530 and Tyr A385 with the best scoring value in compound 8 is -8.0976 and the receptor 3HS6 include Ser A530, Tyr A385, Tyr A355 with the best scoring value in compound 1 is -6.34934. QSAR models show the best QSAR equation: Log (1/IC50) = -92.2384 + 0.5327 AM1_dipole + (-0.00049) AM1_E + 13.3123 log S + 35.7654 mr + (-0.5770 VSA).

References

Billones, Junie B., Salvador M. B. Quantitative Structure-Activity Relationship (QSAR) Study of Cyclooxygenase-2 (COX-2) Inhibitor. Philipine Journal of Science, 140(2), 125-132. 2011

Hermanson, D. J., Lawrence J.M.Cannabinoid, Endocannabinoid and Cancer. Cancer Metastasis Rev. December : 30(3-4): 599-612. 2011

Imaniastuti, Riski. Simulasi Dinamika Molekul Neuraminidase Virus Influenza Subtipe H1n1 Dengan Inhibitor Potensial Peptida Siklis Disulfida (DNY, LRL, NNY). FMIPA UI. 33-34. 2011

National Prescribing Service (NPS). COX-2-Selective NSAIDs : New Wonder Drugs? .2010

Warner, T. D., Jane A. M. Cyclooxygenase: new forms, new inhibitor, and lessons from the clinic. FASEB J. 18, 790-804. 2004

Windsor, M. A., Daniel J. H. Substrate-Selective Inhibition of Cyclooxygenase-2: Development and Evaluation of Achiral Profen Probes. ACS med. Chem. Lett. 3, 759-763. 2012

Published
2017-02-20
Abstract viewed = 529 times